Drug Approval | October 26, 2022
Zydus receives final approval from USFDA for Micafungin for Injection
Micafungin for Injection had annual sales of US $99 million in the United States according to IQVIA data
Micafungin for Injection had annual sales of US $99 million in the United States according to IQVIA data
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 112 million in the U.S. (IQVIA MAT August 2022).
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US
Esiloc was launched at the biggest doctor engagement webinar involving more than 12,000 doctors across the country
The award recognizes Parexel for delivering the best decentralized trial experience for customers through its capabilities, expertise, and patient recruitment and retention strategies
Revenue from operations up 26% to Rs. 768 crores
MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
